Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, presented new data from the ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis (MF) previously treated with or ineligible for JAK inhibitor therapy at the 64th American Society of Hematology (ASH) Annual Meeting & […]

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced that its partner Sanofi has commenced dosing in a Phase 2 study […]

NHP-specific ELISAs now available from Quansys Biosciences

Utah’s vibrant life sciences industry was on full display January 27 as part of the Governor’s Office of Economic Opportunity “Life Sciences Day on the Hill”. The event, held at the state capitol, provided lawmakers the opportunity to interact one-on-one with leaders from local med tech, biotech and diagnostics companies. More than two dozen companies […]

SALT LAKE CITY, Jan. 20, 2023 /PRNewswire/ — Biomerics, the leading vertically integrated medical device contract manufacturer in the interventional device market, announced completion of a 26,000 sq. ft. expansion of its Monroe, CTfacility.  The Monroe facility is the headquarters of Biomerics’ micro-metals processing business and specializes in the design, development, and manufacture of complex […]

Intermountain Healthcare has now officially changed its name to Intermountain Health, reflecting an added emphasis on keeping people healthy, as well as continuing to provide world-class medical care at its hospitals and clinics. Intermountain Health announced the name change in 2022 and that the name would be officially changed in 2023. The name change was […]

DiscGenics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to IDCT for Degenerative Disc Disease

POSITIVE TWO-YEAR CLINICAL DATA ANNOUNCED FOR STUDY OF DISCOGENIC PROGENITOR CELL THERAPY (IDCT) FOR DEGENERATIVE DISC DISEASE